FDA accelerates review of ViiV's HIV/AIDS drug dolutegravir

02/18/2013 | Yahoo

ViiV Healthcare, a joint venture of GlaxoSmithKline, Pfizer and Shionogi, obtained priority-review status from the FDA for its investigational daily AIDS/HIV treatment dolutegravir. The drug is an integrase inhibitor that keeps the virus out of cells. The FDA is set to decide on the drug's approval by Aug. 17.

View Full Article in:

Yahoo

Published in Briefs:

SmartBrief Job Listings for Health Care